abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastické činidlá - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
lunsumio
roche registration gmbh - mosunetuzumab - lymfóm, folikulárny - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
ofost 10 iu/ml injekčný/infúzny roztok
as grindeks, lotyšsko - oxytocín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
ofost 5 iu/ml injekčný/infúzny roztok
as grindeks, lotyšsko - oxytocín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
vancomycin kabi 500 mg
fresenius kabi s.r.o., Česká republika - vankomycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
vancomycin kabi 1 000 mg
fresenius kabi s.r.o., Česká republika - vankomycín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
dexmedetomidine ever pharma 100 mikrogramov/ml koncentrát na infúzny roztok
ever valinject gmbh, rakúsko - dexmedetomidín - 57 - hypnotica, sedativa
anidulafungin fresenius kabi 100 mg
fresenius kabi s.r.o., Česká republika - anidulafungín - 26 - antimycotica (lokÁlne a celkovÉ)